Maria Τektonidou: TMN Manifestation Scores and Mortality in Antiphospholipid Syndrome
Maria Τektonidou, Professor of Rheumatology at National and Kapodistrian University of Athens, shared a post on LinkedIn, about a recent article she and her colleagues co-authored, adding:
“Further Validation of the Eular Antiphospholipid syndrome disease activity score (Eapsdas). Criterion Validity using mortality as the criterion.
The maximum scores of thrombotic/microvascular/non-thrombotic (TMN) manifestations were significantly higher among patients who died due to Antiphospholipid Syndrome than among those who survived and those who died from other causes”
Title: Criterion validity of the EULAR Antiphospholipid Syndrome Disease Activity Score (EAPSDAS)
Authors: Maria G. Tektonidou, Ricard Cervera , Guillermo J. Pons-Estel , Savino Sciascia, Angela Tincani , Michael M. Ward
Read the Full Article on Annals of the Rheumatic Diseases
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids